Piper Jaffray Cos. (PJC) is Trading Lower on Unusual Volume for December 21

Equities Staff |

Piper Jaffray Cos. (PJC) experienced unusually high volume on Dec. 21, as the stock lost 2.04% to a closing price of $39.38. The stock saw 406,052 shares trade hands over the course of the day on 1,796 trades. Given that the stock’s average daily volume over the last month has been 169,393 shares a day, this represents a pretty substantial spike over the norm.

Piper Jaffray Cos. has a P/B ratio of 0.75. It also has a P/E ratio of 12.3. The stock has traded between $59.29 and $33.17 over the last 52-weeks, its 50-day SMA is now $38.23, and its 200-day SMA $44.09.

Piper Jaffray Cos is an investment bank and asset management firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the U.S. and internationally.

Headquartered in Minneapolis, MN, Piper Jaffray Cos. has 1,055 employees and is currently under the leadership of CEO Andrew S. Duff.

For a complete fundamental analysis analysis of Piper Jaffray Cos., check out Equities.com’s Stock Valuation Analysis report for PJC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…